Paul Garofolo

Paul Garofolo is the Co-founder & CEO of Locus Biosciences, a clinical stage biotechnology company focused on the discovery and development of precision medicines using engineered bacteriophage for antimicrobial and microbiome indications. Located in Research Triangle Park, North Carolina, Locus is one of the leading emerging biotechnology companies in the Triangle focused on advancing drug products into the clinic.

Paul has been a member of multiple Executive Management teams of both publicly traded multi-national corporations and successful startup opportunities. Prior to Locus Biosciences, Paul was the Chief Technology Officer for Patheon Pharmaceuticals where he led Global Operations for Patheon’s Pharmaceutical Development Services Division. One of the world leaders in Contract Manufacturing Outsourcing, his teams around the world led the development of all clinical trial materials programs for their Patheon’s clients. Prior to Patheon he served as the Global Head of Manufacturing & Supply and Chief Information Officer for Valeant Pharmaceuticals.

Paul also works on the Board of Directors for Kinvard Bio, a spin-out from the prestigious Myers Lab at Harvard University’s Department of Chemistry and Chemical Biology, pioneering the development of a new and differentiated class of ribosome-targeting antibacterials known as oxepanoprolinamides (OPPs). Paul earned a BSBA in Management Information Systems from the University of Arizona and completed the Advanced Management Program at Harvard Business School.